Last reviewed · How we verify
TA-7284
At a glance
| Generic name | TA-7284 |
|---|---|
| Sponsor | Tanabe Pharma Corporation |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the PK/PD and Safety of TA-7284 in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment (PHASE1)
- Long-Term Safety Study of TA-7284 in Patients With Type 2 Diabetes Mellitus (PHASE3)
- Efficacy and Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus (PHASE4)
- Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With GLP-1 Analogue in Patients With Type 2 Diabetes Mellitus (PHASE4)
- An Efficacy, Safety, and Tolerability Study for TA-7284 in Patients With Type 2 Diabetes (PHASE2)
- Efficacy and Safety Study of TA-7284 in Patients With Type 2 Diabetes (PHASE3)
- Safety, Pharmacokinetics and Pharmacodynamics of TA-7284 in Type 2 Diabetic Patients (PHASE1, PHASE2)
- Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TA-7284 CI brief — competitive landscape report
- TA-7284 updates RSS · CI watch RSS
- Tanabe Pharma Corporation portfolio CI